Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA approves first Parkinson’s dyskinesia drug

The FDA approved Adamas Pharmaceuticals Inc’s treatment for a side effect caused by a commonly prescribed Parkinson’s drug.

Read More »

Last ‘bare county’ in U.S. to get health insurer next year

Ohio’s Department of Insurance said non-profit managed care company CareSource will sell health plans in Paulding County in 2018 – the last county in the United States that would have been without Obamacare individual coverage during the year.

Read More »

ISPOR/ISPE Announce Plans for “Summit on Real-World Evidence in Health Care Decision Making”

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the International Society for Pharmacoepidemiology (ISPE) announced their plans for a one-day conference focused on real-world evidence.

Read More »

Novel Gene Therapy Shows Three-Fold Improvement in Recurrence-Free Survival in High-Risk, Early-Stage Bladder Cancer Patients Where Current Gold-Standard Treatment Fails

The Society of Urologic Oncology and the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC) announced that the Journal of Clinical Oncology published results from a Phase II clinical study led by the SUO-CTC demonstrating the potential effectiveness of Instiladrin (rAD-IFN/Syn3) in patients with high grade, BCG refractory or relapsed Non-Muscle Invasive Bladder Cancer.

Read More »

Job Cuts and Facility Reductions Loom Over SoCal’s ImmunoCellular

Financial concerns continue to plague ImmunoCellular Therapeutics as the company continues to look for cost-cutting measures that will provide enough resources to fund continued R&D on the company’s Stem-to-T-Cell research program.

Read More »

New data boosts case for extended use of AstraZeneca heart drug

AstraZeneca’s blood-thinner Brilinta cuts the risk of cardiovascular death by 29 percent in patients with a history of past heart attacks who keep taking it beyond the standard 12-month initial period, according to new clinical trial data.

Read More »

EU approves breast cancer drug Kisqali

Novartis AG’s Kisqali (ribociclib) received European Union approval as first-line treatment for a tough-to-treat breast cancer.

Read More »

FDA grants priority review to hemophilia drug

Swiss pharma group Roche said the U.S. Food and Drug Administration granted priority review to its emicizumab for hemophilia A with inhibitors.

Read More »

GSW Names Sonja Foster-Storch President

GSW, an INC Research/inVentiv Health company and industry leader in healthcare advertising, named Sonja Foster-Storch as President. Foster-Storch reports to Lisa Stockman, President of inVentiv Health Communications.

Read More »

Vision loss associated with cognitive decline, dementia

Hearing impairment is already linked to a heightened risk of cognitive decline in old age, and a new study suggests that impaired vision may carry the same risk.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom